Demeta Bio's oral LDHA inhibitor MP-5342 targets overactive immune cells
Overview
Demeta Bio says its oral small-molecule LDHA inhibitor MP-5342, co-developed with XtalPi, blocks glycolysis in overactive immune cells to restore immune balance without broad suppression.
The company reports a safety window above 600 times, against a typical threshold of 40 times. It plans Phase I trials in healthy volunteers in 2027 and Phase IIa patient trials in 2028. The figures come from the company and have not been independently verified.
Written by AI from the articles below · updated Oct 30, 8:45 AM ET
Check the sources:
Article timeline
The articles in this story. Times are ET.
- LeiphoneNewsDemeta Bio's oral LDHA inhibitor MP-5342 starves overactive immune cells of energy
AIDemeta Bio says its oral small-molecule LDHA inhibitor MP-5342, co-developed with XtalPi, targets glycolysis in overactive immune cells to restore immune balance without broad suppression. The company reports a safety window above 600 times, far beyond the typical threshold of 40 times, and plans to enter Phase I trials in healthy volunteers in 2027 and Phase IIa patient trials in 2028.
Heat Trend
- Current comparable heat
- 9
- Peak comparable heat
- 9Oct 30, 9:00 AM ET
- Change in past 24 hours
- –
The trend compares only continuously observed participants, so its scope may be smaller than the current heat total. Hover or tap for hourly heat; use arrow keys with a keyboard.